ASPEN has published Clinical Considerations for Neonatal Starter Parenteral Nutrition in response to the announced discontinuation of certain 503B sterile compounding services that have historically supplied neonatal starter PN. The resource provides considerations to help healthcare organizations maintain safe and timely access to neonatal starter PN as availability changes. Topics include indications, formulation considerations, beyond-use dating, compounding, institutional risk assessment, standardized processes, and interprofessional collaboration.
ASPEN thanks the subject matter experts who contributed their expertise to this resource: Petrea Cober, PharmD, MEd, BCNSP, BCPPS, FASPEN; Margaret Murphy, PharmD, BCNSP; Kara Calkins, MD; Kathleen Gura, PharmD, BCNSP, FASHP, FASPEN, FPPA, FMSHP; Diana Mulherin, PharmD, BCNSP, BCCCP, FCCM, FASPEN; and Sarah Cogle, PharmD, BCCCP, BCNSP, FCCM, FASPEN.
Please review the clinical considerations and share them with colleagues.
To support clinicians managing other PN product shortages, ASPEN maintains a collection of PN Product Shortage Recommendations. Access the recommendations and share them with your colleagues.